Marcadia Biotech, an Indianapolis biotech focused on diabetes and obesity, raised $15 million in a first round of funding led by Frazier Healthcare Ventures and founding investor 5AM Ventures. Founding investor Twilight Venture Partners also joined the round. The company’s announcement is here.
Marcadia, founded by former execs from Eli Lilly and Guidant, is developing a stable form of glucagon that could be administered to diabetics when their blood sugar drops precipitously, a state called hypoglycemic shock that can lead to coma and death.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.